AI Analysis

Log in to generate an AI summary for this stock.

Log in to generate a MOAT report for this stock.

Log in to generate an earnings report for this stock.

Log in to generate an operating leverage report for this stock.

Log in to generate a management report for this stock.

Log in to generate a valuation report for this stock.

Biofrontera Inc.

$1.36 +$0.64 (+87.59%)
NASDAQ · 14 Sep 2026 20:00 UTC
Previous Close
$1.55
Day Range
$1.35$1.57
Year Range
$0.56$1.66
Market Cap
17.41M
AVG Volume
423.62K
Trailing/Forward PE
-2.27/6.8
PEG ratio
0.01
Dividend Yield
-
Next Earnings Date
2026-11-11
Primary Exchange
NASDAQUS
Revenue (USD) · TTM
020M40M60M24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
BFRI Revenue (USD) · TTM by quarter
PeriodRevenue (USD) · TTM
26 Q246.17M
26 Q143.2M
25 Q441.71M
25 Q337.16M
25 Q239.19M
25 Q138M
24 Q437.31M
24 Q335.35M
24 Q235.23M
24 Q133.24M
Net Income (USD) · TTM
-30M-20M-10M024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
BFRI Net Income (USD) · TTM by quarter
PeriodNet Income (USD) · TTM
26 Q2-6.37M
26 Q1-11.09M
25 Q4-10.54M
25 Q3-17.57M
25 Q2-16.59M
25 Q1-11.53M
24 Q4-17.76M
24 Q3-12.84M
24 Q2-13.51M
24 Q1-23.09M
Operating Income (USD) · TTM
-30M-20M-10M024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
BFRI Operating Income (USD) · TTM by quarter
PeriodOperating Income (USD) · TTM
26 Q2-4.36M
26 Q1-8.92M
25 Q4-9.15M
25 Q3-17.62M
25 Q2-16.3M
25 Q1-16.29M
24 Q4-17.21M
24 Q3-19.36M
24 Q2-19.02M
24 Q1-22.65M
EBITDA (USD) · TTM
-30M-20M-10M024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
BFRI EBITDA (USD) · TTM by quarter
PeriodEBITDA (USD) · TTM
26 Q2-5.63M
26 Q1-10M
25 Q4-9.18M
25 Q3-16.28M
25 Q2-15.3M
25 Q1-9.64M
24 Q4-14.48M
24 Q3-9.31M
24 Q2-9.9M
24 Q1-20.05M
Cash Flows (USD) · TTM
-30M-20M-10M024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
BFRI Cash Flows (USD) · TTM by quarter
PeriodCash Flows (USD) · TTM
26 Q2-7.93M
26 Q1-9.32M
25 Q4-13.36M
25 Q3-12.01M
25 Q2-9.39M
25 Q1-11.07M
24 Q4-10.33M
24 Q3-18.17M
24 Q2-18.96M
24 Q1-24.58M
EPS (USD) · TTM
-15-10-5024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
BFRI EPS (USD) · TTM by quarter
PeriodEPS (USD) · TTM
26 Q2-0.6
26 Q1-1.12
25 Q4-1.47
25 Q3-2.14
25 Q2-2.5
25 Q1-1.98
24 Q4-4.1
24 Q3-2.26
24 Q2-5.92
24 Q1-13.1
Expenses (USD) · TTM
020M40M60MR&DSG&ACapex24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
BFRI Expenses (USD) · TTM by quarter
PeriodExpenses (USD) · TTM
26 Q242.69M
26 Q144.01M
25 Q441.95M
25 Q341.48M
25 Q239.38M
25 Q136.51M
24 Q435.99M
24 Q336.07M
24 Q235.7M
24 Q138.68M
Shares Outstanding · TTM
-1.5M-1M-500K024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
BFRI Shares Outstanding · TTM by quarter
PeriodShares Outstanding · TTM
26 Q2-1.13M
26 Q1-1.05M
25 Q4-951K
25 Q3-961K
25 Q2-1.01M
25 Q1-1.03M
24 Q4-1.02M
24 Q3-948K
24 Q2-867K
24 Q1-922K
Employee Count
025507510020212022202320242025
BFRI Employee Count by quarter
PeriodEmployee Count
202572
202492
202383
202281
202169
Free Cash Flow Yield
-500%-400%-300%-200%-100%0%med -136.31%Dec 24Apr 25Jul 25Nov 25Feb 26Jun 26Sep 26
BFRI Free Cash Flow Yield by quarter
PeriodFree Cash Flow Yield
Sep 26-45.12%
Sep 26-39.59%
Sep 26-38.11%
Aug 26-38.59%
Aug 26-41.46%
Aug 26-47.2%
Aug 26-62.8%
Jul 26-68.17%
Jul 26-73.17%
Jul 26-73.17%
Jul 26-72.5%
Jul 26-78.97%
Jun 26-82.14%
Jun 26-80.81%
Jun 26-92.19%
Jun 26-85.3%
May 26-90.02%
May 26-98.79%
May 26-99.69%
May 26-99.76%
May 26-106.22%
Apr 26-106.22%
Apr 26-104.29%
Apr 26-111.38%
Apr 26-117.07%
Mar 26-140.07%
Mar 26-131.86%
Mar 26-128.11%
Mar 26-129.69%
Feb 26-122.21%
Feb 26-125.78%
Feb 26-143.07%
Feb 26-135.7%
Jan 26-119.75%
Jan 26-111.41%
Jan 26-133.81%
Jan 26-135.12%
Jan 26-153.66%
Dec 25-154.47%
Dec 25-145.44%
Dec 25-137.15%
Dec 25-133.33%
Nov 25-136.38%
Nov 25-150.59%
Nov 25-136.24%
Nov 25-92.99%
Oct 25-91.3%
Oct 25-91.3%
Oct 25-104.62%
Oct 25-104.62%
Oct 25-93.86%
Sep 25-104.63%
Sep 25-111.59%
Sep 25-119.39%
Sep 25-118.95%
Aug 25-113.34%
Aug 25-104.22%
Aug 25-107.99%
Aug 25-211.98%
Aug 25-192.92%
Jul 25-189.28%
Jul 25-227.43%
Jul 25-233.3%
Jul 25-286.63%
Jun 25-333.51%
Jun 25-327.84%
Jun 25-304.46%
Jun 25-334.4%
May 25-357.01%
May 25-313.6%
May 25-308.82%
May 25-269.48%
May 25-260.09%
Apr 25-231.33%
Apr 25-220.31%
Apr 25-222.93%
Apr 25-253.06%
Mar 25-230.33%
Mar 25-217.75%
Mar 25-339.98%
Mar 25-342.03%
Feb 25-322.64%
Feb 25-283.49%
Feb 25-266.67%
Feb 25-273.63%
Jan 25-278.47%
Jan 25-288.69%
Jan 25-286.06%
Jan 25-280.95%
Jan 25-280.95%
Dec 24-283.49%
Dec 24-321.58%
Dec 24-296.86%
Dec 24-314.67%
Nov 24-349.63%
Nov 24-361.69%
Nov 24-428.71%
Nov 24-435.11%
Nov 24-341.74%
Oct 24-410.42%
Price to Sales
00.10.20.30.40.5med 0.22Dec 24Apr 25Jul 25Nov 25Feb 26Jun 26Sep 26
BFRI Price to Sales by quarter
PeriodPrice to Sales
Sep 260.38
Sep 260.43
Sep 260.45
Aug 260.45
Aug 260.41
Aug 260.36
Aug 260.34
Jul 260.32
Jul 260.29
Jul 260.29
Jul 260.3
Jul 260.27
Jun 260.26
Jun 260.27
Jun 260.23
Jun 260.25
May 260.24
May 260.22
May 260.22
May 260.32
May 260.3
Apr 260.3
Apr 260.31
Apr 260.29
Apr 260.27
Mar 260.23
Mar 260.24
Mar 260.25
Mar 260.25
Feb 260.26
Feb 260.26
Feb 260.23
Feb 260.24
Jan 260.27
Jan 260.29
Jan 260.24
Jan 260.24
Jan 260.21
Dec 250.21
Dec 250.22
Dec 250.24
Dec 250.24
Nov 250.24
Nov 250.21
Nov 250.24
Nov 250.26
Oct 250.26
Oct 250.26
Oct 250.23
Oct 250.23
Oct 250.26
Sep 250.23
Sep 250.21
Sep 250.2
Sep 250.2
Aug 250.21
Aug 250.23
Aug 250.22
Aug 250.14
Aug 250.15
Jul 250.15
Jul 250.13
Jul 250.12
Jul 250.1
Jun 250.09
Jun 250.09
Jun 250.1
Jun 250.09
May 250.08
May 250.09
May 250.09
May 250.1
May 250.11
Apr 250.12
Apr 250.13
Apr 250.12
Apr 250.11
Mar 250.12
Mar 250.13
Mar 250.15
Mar 250.15
Feb 250.16
Feb 250.18
Feb 250.19
Feb 250.19
Jan 250.18
Jan 250.18
Jan 250.18
Jan 250.18
Jan 250.18
Dec 240.18
Dec 240.16
Dec 240.17
Dec 240.16
Nov 240.15
Nov 240.14
Nov 240.12
Nov 240.12
Nov 240.16
Oct 240.13
EV/EBITDA
-11.5-11-10.5-10-9.5med -10.99Mar 23Apr 23Apr 23May 23
BFRI EV/EBITDA by quarter
PeriodEV/EBITDA
May 23-11.19
Apr 23-11.42
Apr 23-10.42
Apr 23-11.28
Apr 23-11.14
Mar 23-10.85
Mar 23-10.56
Mar 23-9.71
Price to Book
051015med 1.17Feb 24Sep 24Dec 24Apr 25Jul 25Jun 26Sep 26
BFRI Price to Book by quarter
PeriodPrice to Book
Sep 262.95
Sep 263.36
Sep 263.49
Aug 263.45
Aug 263.21
Aug 262.82
Aug 262.44
Jul 262.25
Jul 262.1
Jul 262.1
Jul 262.12
Jul 261.94
Jun 261.87
Jun 261.9
Jun 261.67
Jun 261.8
May 261.71
May 261.55
May 261.54
May 261.28
May 261.2
Apr 261.2
Apr 261.22
Apr 261.14
Apr 261.09
Mar 260.91
Mar 260.97
Aug 2511.13
Aug 2512.23
Jul 2512.47
Jul 2510.38
Jul 2510.12
Jul 258.23
Jun 257.08
Jun 257.2
Jun 257.75
Jun 257.06
May 256.61
May 257.53
May 257.64
May 250.86
May 250.9
Apr 251.01
Apr 251.06
Apr 251.05
Apr 250.92
Mar 251.01
Mar 251.07
Mar 250.97
Mar 250.96
Feb 251.02
Feb 251.16
Feb 251.23
Feb 251.2
Jan 251.18
Jan 251.14
Jan 251.15
Jan 251.17
Jan 251.17
Dec 241.16
Dec 241.02
Dec 241.11
Dec 241.04
Nov 240.94
Nov 240.91
Nov 240.77
Nov 240.4
Nov 240.51
Oct 240.42
Oct 240.39
Oct 240.37
Oct 240.45
Sep 240.6
Sep 240.6
Sep 240.6
Sep 240.52
Aug 240.51
Aug 240.55
Aug 240.63
May 240.56
May 240.77
Apr 240.71
Apr 240.75
Apr 240.93
Apr 240.81
Mar 240.69
Mar 240.54
Mar 240.69
Mar 241.61
Mar 241.17
Feb 241.21
Feb 240.99
Feb 240.96
Feb 241.21
Jan 241.99
Jan 242.16
Jan 242.91
Jan 243.71
Dec 233.65
Dec 233.9
Biofrontera Inc.
BFRI
Stockpicker

Video analysis: BFRI

All videos

No video analysis for this stock yet. Request one from our team.

Your email is used only to follow up on this request. We do not add you to marketing lists. Privacy Policy

News: BFRI

Biofrontera Announces FDA Approval of Ameluz® Red Light PDT for the Treatment of Superficial Basal Cell Carcinoma

globenewswire.com · 14 Sep 2026

Biofrontera Announces FDA Approval of Ameluz® Red Light PDT for the Treatment of Superficial Basal Cell Carcinoma

Ameluz used in conjunction with the RhodoLED lamp becomes the first and only photodynamic therapy approved in the United States to treat a skin cancer, creating an additional growth opportunity for Biofrontera's photodynamic therapy platform

Biofrontera Inc. (BFRI) Q2 2026 Earnings Call Transcript

seekingalpha.com · 13 Aug 2026

Biofrontera Inc. (BFRI) Q2 2026 Earnings Call Transcript

Biofrontera Inc. (BFRI) Q2 2026 Earnings Call Transcript

Biofrontera Inc. (BFRI) Reports Q2 Loss, Beats Revenue Estimates

zacks.com · 13 Aug 2026

Biofrontera Inc. (BFRI) Reports Q2 Loss, Beats Revenue Estimates

Biofrontera Inc. (BFRI) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to a loss of $0.57 per share a year ago.

Biofrontera Inc. Reports Strong Second Quarter 2026 Financial Results Driven by 33% Revenue Growth

globenewswire.com · 13 Aug 2026

Biofrontera Inc. Reports Strong Second Quarter 2026 Financial Results Driven by 33% Revenue Growth

WOBURN, Mass., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ: BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT) in dermatology, today reported financial results for the quarter ended June 30, 2026.

Biofrontera Inc. to Report Second Quarter 2026 Financial Results on August 13, 2026

globenewswire.com · 5 Aug 2026

Biofrontera Inc. to Report Second Quarter 2026 Financial Results on August 13, 2026

WOBURN, Mass., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ: BFRI) ("Biofrontera" or the "Company"), a U.S. specialty dermatology company commercializing Ameluz® (aminolevulinic acid hydrochloride) Gel, 10% with the BF-RhodoLED® lamp for photodynamic therapy (PDT) of actinic keratosis, today announced that it will report financial results for the second quarter ended June 30, 2026 before the market opens on Thursday, August 13, 2026.

Similar companies

Disclaimer: The historical data presented on this platform is provided by Financial Modeling Prep. Stock Picker is a platform for informational purposes only and does not provide financial advice. Users are encouraged to conduct their own research and consult with a qualified financial advisor before making investment decisions.